Cyclophosphamide (CTX) and high-dose 4-Epidoxorubicin (EPI) in advanced ovarian cancer (OC) treatment

1994 ◽  
pp. 469-472
Author(s):  
G. Cartei ◽  
M. Signor ◽  
E. Vigevani ◽  
M. Giovannoni ◽  
A. Sibau ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Advanced Ovarian Cancer ◽  
High Dose

Maximal Cytoreductive Surgery and High Dose Cisplatin Chemotherapy for Advanced Ovarian Cancer

2010 ◽  
Vol 19 (4) ◽  
pp. 375-381 ◽  
Author(s):  
Kazunori Ochiai ◽  
Satoshi Takakura ◽  
Seiji Isonishi ◽  
Hiroshi Sasaki ◽  
Yoshiteru Terashima
Keyword(s):  
Ovarian Cancer ◽  
Cytoreductive Surgery ◽  
Advanced Ovarian Cancer ◽  
High Dose

Phase III Trial of High-Dose Sequential Chemotherapy With Peripheral Blood Stem Cell Support Compared With Standard Dose Chemotherapy for First-Line Treatment of Advanced Ovarian Cancer: Intergroup Trial of the AGO-Ovar/AIO and EBMT

2007 ◽  
Vol 25 (27) ◽  
pp. 4187-4193 ◽  
Author(s):  
Volker Möbus ◽  
Hannes Wandt ◽  
Norbert Frickhofen ◽  
Carmelo Bengala ◽  
Kim Champion ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Peripheral Blood Stem Cell ◽  
Standard Dose ◽  
Advanced Ovarian Cancer ◽  
Progression Free Survival ◽  
High Dose ◽  
First Line ◽  
Sequential Chemotherapy ◽  
Free Survival ◽  
First Line Treatment

PurposeAlthough ovarian cancer is one of the most chemotherapy-sensitive solid tumors, cure after radical surgery and chemotherapy is uncommon. A randomized trial comparing high-dose sequential chemotherapy with peripheral blood stem cell (PBSC) support with platinum-based combination chemotherapy was conducted to investigate whether dose-intensification improves outcome.Patients and MethodsOne hundred forty-nine patients with untreated ovarian cancer were randomly assigned after debulking surgery to receive standard combination chemotherapy or sequential high-dose (HD) treatment with two cycles of cyclophosphamide and paclitaxel followed by three cycles of HD carboplatin and paclitaxel with PBSC support. HD melphalan was added to the final cycle. The median age was 50 years (range, 20 to 65 years) and International Federation of Gynecology and Obstetrics stage was IIb/IIc in 4%, III in 78%, and IV in 17%.ResultsSeventy-six percent of patients received all five cycles in the HD arm and the main toxicities were neuro-/ototoxicity, gastrointestinal toxicity, and infection and one death from hemorrhagic shock. After a median follow-up of 38 months, the progression-free survival was 20.5 months in the standard arm and 29.6 months in the HD arm (hazard ratio [HR], 0.84; 95% CI, 0.56 to 1.26; P, .40). Median overall survival (OS) was 62.8 months in the standard arm and 54.4 months in the HD arm (HR, 1.17; 95% CI, 0.71 to 1.94; P, .54).ConclusionThis is the first randomized trial comparing sequential HD versus standard dose chemotherapy in first-line treatment of patients with advanced ovarian cancer. We observed no statistically significant difference in progression-free survival or OS and conclude that HD chemotherapy does not appear to be superior to conventional dose chemotherapy.

High-Dose Topotecan, Melphalan, and Cyclophosphamide (TMC) with Stem Cell Support: A New Regimen for the Treatment of Advanced Ovarian Cancer

2001 ◽  
Vol 82 (3) ◽  
pp. 420-426 ◽  
Author(s):  
Michele L. Donato ◽  
David M. Gershenson ◽  
James T. Wharton ◽  
Cindy M. Ippoliti ◽  
Ana S. Aleman ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Stem Cell ◽  
Advanced Ovarian Cancer ◽  
High Dose ◽  
Stem Cell Support ◽  
Cell Support
Sign in / Sign up

Export Citation Format

Share Document